These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

Bayer’s BlueRock Therapeutics outfit announced Jan. 13 in tandem with the annual J.P. Morgan Healthcare Conference. The phase 3 trial, dubbed exPDite-2, is expected to enroll 102 people with ...